Real-world effectiveness of fremanezumab in patients with migraine switching from  another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

ConclusionsOur results show that about 42.8% of anti-CGRP pathway  mAb-non-responder benefit from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing poor tolerability or inadequate efficacy with prior other anti-CGRP pathway mAb use.Trial registrationFinesse Study is registered on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS44606).Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research